These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 9278467)

  • 41. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.
    Shorr AF; Jackson WL; Weiss BM; Moores LK
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):309-16. PubMed ID: 17473570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Letter 1: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Wille-Jorgensen P
    Br J Surg; 2006 Mar; 93(3):374; author reply 375-6. PubMed ID: 16498577
    [No Abstract]   [Full Text] [Related]  

  • 43. [Anticoagulation with low molecular weight heparins within the framework of cardioversion for atrial fibrillation].
    Tebbe U
    Dtsch Med Wochenschr; 2007 Sep; 132(39):2033-6. PubMed ID: 17882745
    [No Abstract]   [Full Text] [Related]  

  • 44. [Cost-effectiveness of the prevention of postoperative thromboembolism].
    Bergqvist D; Mätzsch T
    Orthopade; 1993 Apr; 22(2):140-3. PubMed ID: 8388560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Tangelder MJ; Bylock A; Held P
    Br J Surg; 2006 Mar; 93(3):374-5; author reply 375-6. PubMed ID: 16498578
    [No Abstract]   [Full Text] [Related]  

  • 47. Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Agnelli G; Bergqvist D; Dahl O; Eriksson B; Rud Lassen M; Mouret P; Rosencher N
    Br J Surg; 2006 Mar; 93(3):375; author reply 375-6. PubMed ID: 16498579
    [No Abstract]   [Full Text] [Related]  

  • 48. Low molecular weight heparins in cardiovascular medicine.
    De Lorenzo F; Dotsenko O; Kakkar VV
    Minerva Cardioangiol; 2005 Dec; 53(6):585-603. PubMed ID: 16333240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Deep venous thrombosis: outpatient therapy with low-molecular-weight heparin.
    Tapson VF
    Manag Care; 1999 Dec; 8 Suppl():2-6. PubMed ID: 11729399
    [No Abstract]   [Full Text] [Related]  

  • 50. Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis.
    Kakkar VV
    Thromb Res; 1996; 81(2 Suppl):S75-7. PubMed ID: 8822130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Low molecular weight heparin: the first 5 years].
    Mannucci PM
    Ann Ital Med Int; 1997; 12(2):61-2. PubMed ID: 9333314
    [No Abstract]   [Full Text] [Related]  

  • 52. Low molecular weight heparins: are they interchangeable? No.
    Nenci GG
    J Thromb Haemost; 2003 Jan; 1(1):12-3. PubMed ID: 12871532
    [No Abstract]   [Full Text] [Related]  

  • 53. Treat DVT with low molecular weight heparin.
    Nadeau C; Varrone J
    Nurse Pract; 2003 Oct; 28(10):22-9; quiz 30-1. PubMed ID: 14560128
    [No Abstract]   [Full Text] [Related]  

  • 54. Low-molecular-weight herapin.
    Whang PG; Lieberman JR
    J Am Acad Orthop Surg; 2002; 10(5):299-302. PubMed ID: 12374480
    [No Abstract]   [Full Text] [Related]  

  • 55. [Use of low molecular weight heparins in thromboembolic disease].
    Zuazu-Jausoro I; Lozano ML; Vicente V
    Rev Clin Esp; 2000 Aug; 200(8):447-8. PubMed ID: 11076184
    [No Abstract]   [Full Text] [Related]  

  • 56. [Not Available].
    Graf L; Korte W
    Ther Umsch; 2016; 73(10):545-549. PubMed ID: 28045364
    [No Abstract]   [Full Text] [Related]  

  • 57. Prophylactic heparin in palliative care: ...to a challenging idea.
    Chambers JC
    BMJ; 2006 Mar; 332(7543):729. PubMed ID: 16565142
    [No Abstract]   [Full Text] [Related]  

  • 58. Low-molecular-weight heparins: a new generation of anticoagulants.
    Messerschmidt K
    S D J Med; 1998 Feb; 51(2):47-8. PubMed ID: 9509889
    [No Abstract]   [Full Text] [Related]  

  • 59. Up close and personal with low-molecular-weight heparins (LMWHs).
    Lugthart S
    Neth J Med; 2015 Jul; 73(6):261-2. PubMed ID: 26228189
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacology of second generation low molecular weight heparins.
    Carrasco P
    Pathophysiol Haemost Thromb; 2002; 32(5-6):401-2. PubMed ID: 13679685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.